Cell Cycle Regulation of Smooth Muscle Cells—Searching for Inhibitors of Neointima Formation: Is Combretastatin A4 an Alternative to Sirolimus and Paclitaxel?

Tasaki, 2013, Apoptosis signal-regulating kinase 1 deficiency attenuates vascular injury-induced neointimal hyperplasia by suppressing apoptosis in smooth muscle cells, Am J Pathol, 182, 597, 10.1016/j.ajpath.2012.10.008 Hehrlein, 1994, The role of elastic recoil after balloon angioplasty of rabbit arteries and its prevention by stent implantation, Eur Heart J, 15, 277, 10.1093/oxfordjournals.eurheartj.a060487 Marx, 2011, Vascular smooth muscle cell proliferation in restenosis, Circ Cardiovasc Interv, 4, 104, 10.1161/CIRCINTERVENTIONS.110.957332 Sherr, 2000, The Pezcoller lecture: cancer cell cycles revisited, Cancer Res, 60, 3689 Ohtsubo, 1995, Human cyclin E, a nuclear protein essential for the G1-to-S phase transition, Mol Cell Biol, 15, 2612, 10.1128/MCB.15.5.2612 Tanner, 2000, Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation, Circulation, 101, 2022, 10.1161/01.CIR.101.17.2022 Sun, 2001, Role for p27(Kip1) in vascular smooth muscle cell migration, Circulation, 103, 2967, 10.1161/01.CIR.103.24.2967 Finn, 2009, Differential healing after sirolimus, paclitaxel, and bare metal stent placement in combination with peroxisome proliferator-activator receptor gamma agonists: requirement for mTOR/Akt2 in PPARgamma activation, Circ Res, 105, 1003, 10.1161/CIRCRESAHA.109.200519 Drachman, 2000, Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months, J Am Coll Cardiol, 36, 2325, 10.1016/S0735-1097(00)01020-2 Wang, 2000, Paclitaxel-induced cell death: where the cell cycle and apoptosis come together, Cancer, 88, 2619, 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J Levin, 2004, Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel, Proc Natl Acad Sci U S A, 101, 9463, 10.1073/pnas.0400918101 Zeller, 2014, Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial, J Am Coll Cardiol, 64, 1568, 10.1016/j.jacc.2014.06.1198 Cushman, 1991, Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization, J Med Chem, 34, 2579, 10.1021/jm00112a036 Vincent, 2005, Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling, J Clin Invest, 115, 2992, 10.1172/JCI24586 Hayashi, 2009, The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy, Am J Pathol, 175, 2226, 10.2353/ajpath.2009.090152 Dark, 1997, Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature, Cancer Res, 57, 1829 Khan, 1998, p53 and pRb prevent rereplication in response to microtubule inhibitors by mediating a reversible G1 arrest, Cancer Res, 58, 396 Viñals, 1999, p70 S6 kinase-mediated protein synthesis is a critical step for vascular endothelial cell proliferation, J Biol Chem, 274, 26776, 10.1074/jbc.274.38.26776 Braun-Dullaeus, 2001, Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin, Arterioscler Thromb Vasc Biol, 21, 1152, 10.1161/hq0701.092104 Kawamata, 1998, The upregulation of p27Kip1 by rapamycin results in G1 arrest in exponentially growing T-cell lines, Blood, 91, 561, 10.1182/blood.V91.2.561 Morice, 1993, Rapamycin inhibition of interleukin-2-dependent p33cdk2 and p34cdc2 kinase activation in T lymphocytes, J Biol Chem, 268, 22737, 10.1016/S0021-9258(18)41589-X Chaplin D, Wnendt S, Kuttler B, et al. Implants containing combretastatin a-4. Patent DE 20050065595, filed September 2, 2002, and issued March 24, 2005. Tozer, 2002, The biology of the combretastatins as tumour vascular targeting agents, Int J Exp Pathol, 83, 21, 10.1046/j.1365-2613.2002.00211.x Costa, 2005, Molecular basis of restenosis and drug-eluting stents, Circulation, 111, 2257, 10.1161/01.CIR.0000163587.36485.A7